1. Search Result
Search Result
Results for "

retinoic

" in MedChemExpress (MCE) Product Catalog:

83

Inhibitors & Agonists

1

Screening Libraries

3

Fluorescent Dye

3

Biochemical Assay Reagents

4

Peptides

1

Inhibitory Antibodies

6

Natural
Products

22

Recombinant Proteins

9

Isotope-Labeled Compounds

5

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14649
    Retinoic acid
    Maximum Cited Publications
    50 Publications Verification

    Vitamin A acid; all-trans-retinoic acid; ATRA

    Organoid RAR/RXR PPAR Endogenous Metabolite Autophagy Cancer
    Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.
    <em>Retinoic</em> acid
  • HY-14649R
    Retinoic acid (Standard)
    Maximum Cited Publications
    50 Publications Verification

    Vitamin A acid (Standard); all-trans-retinoic acid (Standard); ATRA (Standard)

    RAR/RXR PPAR Endogenous Metabolite Autophagy Cancer
    Retinoic acid (Standard) is the analytical standard of Retinoic acid. This product is intended for research and analytical applications. Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.
    <em>Retinoic</em> acid (Standard)
  • HY-14649S4

    Vitamin A acid-d5; all-trans-retinoic acid-d5; ATRA-d5

    Isotope-Labeled Compounds RAR/RXR PPAR Cancer
    Retinoic acid-d5 is the the deuterium labeled Retinoic acid (HY-14649). Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha .
    <em>Retinoic</em> acid-d5
  • HY-14649G

    Vitamin A acid; all-trans-retinoic acid; ATRA

    RAR/RXR Cancer
    Retinoic acid (Vitamin A acid) (GMP) is Retinoic acid (HY-14649) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Retinoic acid is an agonist of RAR nuclear receptors .
    Retinoic acid
  • HY-14649S3

    Vitamin A acid-d6; all-trans-retinoic acid-d6; ATRA-d6

    RAR/RXR PPAR Autophagy Endogenous Metabolite Cancer
    Retinoic acid-d6 is the deuterium labeled Retinoic acid[1]. Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha[2][3][4][5][6][7].
    <em>Retinoic</em> acid-d6
  • HY-14649S2

    RAR/RXR PPAR Endogenous Metabolite Autophagy Cancer
    11-cis-Retinoic Acid-d5 is the deuterium labeled Retinoic acid. Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha[1][2].
    11-cis-<em>Retinoic</em> Acid-d5
  • HY-132334S

    RAR/RXR Apoptosis Neurological Disease Inflammation/Immunology Cancer
    9-cis-Retinoic acid-d5 is the deuterium labeled 9-cis-Retinoic acid. 9-cis-Retinoic acid (ALRT1057), a vitamin A derivative, is a potent RAR/RXR agonist. 9-cis-Retinoic acid induces apoptosis, regulates cell cycle and has anticancer, anti-inflammatory and neuroprotection activities[1][2][3][4][5][6].
    9-cis-<em>Retinoic</em> acid-d5
  • HY-15128

    Alitretinoin

    RAR/RXR Apoptosis Endogenous Metabolite Neurological Disease Inflammation/Immunology Cancer
    9-cis-Retinoic acid (ALRT1057), a vitamin A derivative, is a potent RAR/RXR agonist. 9-cis-Retinoic acid induces apoptosis, regulates cell cycle and has anticancer, anti-inflammatory and neuroprotection activities .
    9-cis-<em>Retinoic</em> acid
  • HY-108522
    PA452
    1 Publications Verification

    RAR/RXR Metabolic Disease
    PA452, retinoic X receptor (RXR) specific antagonist, inhibits the effect of Retinoic acid (RA) on Th1/Th2 development .
    PA452
  • HY-119359

    Isotretinoin EP impurity G

    Others Others
    5,6-Epoxy-13-cis retinoic acid (Isotretinoin EP impurity G) is a metabolite of 13-cis retinoic acid .
    5,6-Epoxy-13-cis <em>retinoic</em> acid
  • HY-15127
    Isotretinoin
    4 Publications Verification

    13-cis-retinoic acid

    RAR/RXR Endogenous Metabolite Autophagy Cancer
    Isotretinoin (13-cis-Retinoic acid) is an orally active vitamin A derivative and is often be used for the research of severe acne. Isotretinoin also shows anticancer activity .
    Isotretinoin
  • HY-107395

    RAR/RXR Inflammation/Immunology
    BMS 753 is an isotype-selective retinoic acid receptor α (RARα) agonist, with a Ki of 2 nM .
    BMS 753
  • HY-107494A

    all-trans 4-Keto retinoic Acid

    Endogenous Metabolite Metabolic Disease
    all-trans-4-Oxoretinoic acid, an active metabolite of vitamin A, induces gene transcription via binding to nuclear retinoic acid receptors (RARs).
    all-trans-4-Oxoretinoic acid
  • HY-101106
    AR7
    5 Publications Verification

    RAR/RXR Neurological Disease Cancer
    AR7 is an atypical RARA/RARα (retinoic acid receptor, alpha) antagonist. AR7 specifically activates chaperone-mediated-autophagy (CMA) activity without affecting macroautophagy .
    AR7
  • HY-108529
    BMS493
    2 Publications Verification

    RAR/RXR Metabolic Disease
    BMS493 is an inverse pan-retinoic acid receptor (RAR) agonist. BMS493 increases nuclear corepressor interaction with RARs. BMS493 also could prevent retinoic acid-induced differentiation . BMS493 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    BMS493
  • HY-108520

    RAR/RXR Apoptosis Cancer
    HX630 is a potent retinoic acid X receptor (RXR) agonist, can induce apoptosis, has anti-tumor effect, and can be used in Cushing's disease research .
    HX630
  • HY-108531

    RAR/RXR Cancer
    ER-50891 is a potent antagonist of retinoic acid receptor α(RARα). ER-50891 significantly attenuates ATRA's inhibitive effects on BMP 2-induced osteoblastogenesis .
    ER 50891
  • HY-108531A

    RAR/RXR Cancer
    ER 50891 quarterhydrate is a potent antagonist of retinoic acid receptor α(RARα). ER 50891 quarterhydrate significantly attenuates ATRA's inhibitive effects on BMP 2-induced osteoblastogenesis .
    ER 50891 quarterhydrate
  • HY-15682G

    Ro 13-7410; Arotinoid acid; AGN191183

    RAR/RXR Cancer
    TTNPB (Ro 13-7410) (GMP) is TTNPB (HY-15682) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TTNPB is a highly potent retinoic acid receptor (RAR) agonist .
    TTNPB
  • HY-156280

    RAR/RXR Endocrinology
    RARα antagonist 1 (compound 21) is an orally active and selective retinoic acid receptor α(RARα) antagonist, with the IC50 of 4.6nM .
    RARα antagonist 1
  • HY-15870
    SR 11302
    5 Publications Verification

    AP-1 Inflammation/Immunology Cancer
    SR 11302 is an activator protein-1 (AP-1) transcription factor inhibitor. SR 11302 is a retinoid that specifically inhibits AP-1 activity without activating the transcription of retinoic acid response element (RARE) .
    SR 11302
  • HY-116248

    RAR/RXR Apoptosis Cancer
    Ro 41-5253 is an orally active selective retinoic acid receptor alpha (RARα) antagonist. Ro 41-5253 can bind RARα without inducing transcription or affecting RAR/RXR heterodimerization and DNA binding. Ro 41-5253 can inhibit cancer cell proliferation and induce apoptosis, has antitumor activity .
    Ro 41-5253
  • HY-133552

    ROR Inflammation/Immunology
    RORγt Inverse agonist 10 is a potent and orally bioavailable RORγt (retinoic acid receptor-related orphan nuclear receptor gamma t) inverse agonist, with an IC50 of 51 nM. RORγt is a major transcription factor of genes related to psoriasis pathogenesis such as IL-17A, IL-22, and IL-23R
    RORγt Inverse agonist 10
  • HY-119366

    ROR Inflammation/Immunology
    S18-000003 is a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt), with an IC50 of <30 nM towards human RORγt in competitive binding assays. S18-000003 shows selectivity for RORγt over other ROR family members (IC50>10 μM). S18-000003 can be used for the research of psoriasis with low risk of thymic aberrations .
    S18-000003
  • HY-112077

    Others Inflammation/Immunology
    (Z)-Viaminate is a derivative of Retinoic acid.
    (Z)-Viaminate
  • HY-106019

    R75251

    Cytochrome P450 RAR/RXR Metabolic Disease Inflammation/Immunology Cancer
    Liarozole (R75251; R85246) is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of retinoic acid (IC50=7 μM), resulting in increased tissue levels of retinoic acid. Liarozole shows antitumoral properties .
    Liarozole
  • HY-14799
    Palovarotene
    5+ Cited Publications

    R 667; Ro 3300074

    RAR/RXR Autophagy Others
    Palovarotene is a nuclear retinoic acid receptor γ (RAR-γ) agonist.
    Palovarotene
  • HY-100532
    CD437
    2 Publications Verification

    AHPN

    RAR/RXR Autophagy Cancer
    CD437 is a selective Retinoic Acid Receptor γ (RARγ) agonist.
    CD437
  • HY-112077A

    Others Inflammation/Immunology
    Viaminate is a derivative of Retinoic acid, which is used for the treatment of severe acne and other keratinization disorders.
    Viaminate
  • HY-107765
    LY2955303
    2 Publications Verification

    RAR/RXR Autophagy Inflammation/Immunology
    LY2955303 is a potent and selective retinoic acid receptor gamma (RARγ) antagonist with a Ki of 1.09 nM.
    LY2955303
  • HY-14802C

    RAR/RXR Autophagy Cancer
    (+)-Talarozole is a potent inhibitor of retinoic acid metabolism extracted from patent WO 1997049704 A1.
    (+)-Talarozole
  • HY-14802D

    RAR/RXR Autophagy Cancer
    (-)-Talarozole is a potent inhibitor of retinoic acid metabolism extracted from patent WO 1997049704 A1.
    (-)-Talarozole
  • HY-14531
    Talarozole
    15+ Cited Publications

    R115866

    RAR/RXR Cytochrome P450 Autophagy Inflammation/Immunology
    Talarozole (R115866) is an oral systemic all-trans retinoic acid metabolism blocking agent (RAMBA) which increases intracellular levels of endogenous all-trans retinoic acid (RA). Talarozole inhibits both CYP26A1 and CYP26B1 with IC50s of 5.4 and 0.46 nM, respectively.
    Talarozole
  • HY-14652
    Tamibarotene
    5+ Cited Publications

    Am 80

    RAR/RXR Autophagy Apoptosis Cancer
    Tamibarotene is an orally active retinoic acid receptor α (RARα) agonist, showing high selectivity over RARγ.
    Tamibarotene
  • HY-15373
    Fenretinide
    5+ Cited Publications

    4-HPR

    RAR/RXR Autophagy Cancer
    Fenretinide (4-HPR) is a synthetic retinoid deriverative, binding to the retinoic acid receptors (RAR) at concentrations necessary to induce cell death.
    Fenretinide
  • HY-108528

    RAR/RXR Inflammation/Immunology
    BMS961 is a selective retinoic acid receptor-γ (RARγ) agonist. BMS961 shows anti-inflammatory activity .
    BMS961
  • HY-111841

    SNIPERs PROTACs Cancer
    PROTAC CRABP-II Degrader-2 is a potent cellular retinoic acid binding protein (CRABP-II) degrader based on IAP ligand .
    PROTAC CRABP-II Degrader-2
  • HY-111842

    SNIPERs PROTACs Cancer
    PROTAC CRABP-II Degrader-3 is a potent cellular retinoic acid binding protein (CRABP-II) degrader based on IAP ligand .
    PROTAC CRABP-II Degrader-3
  • HY-111840

    SNIPERs PROTACs Cancer
    PROTAC CRABP-II Degrader-1 is a potent cellular retinoic acid binding protein (CRABP-II) degrader based on IAP ligand .
    PROTAC CRABP-II Degrader-1
  • HY-139847

    ROR Inflammation/Immunology
    RORγt inverse agonist 23 is a potent, selective, and orally available novel retinoic acid receptor-related orphan receptor γt inverse agonist.
    RORγt inverse agonist 23
  • HY-14802

    (R)-Talarozole

    Cytochrome P450 Cancer
    Talarozole R enantiomer is a potent and selective inhibitor of cytochrome P450 26-mediated breakdown of endogenous all-trans retinoic acid for the treatment of psoriasis and acne.
    Talarozole (R enantiomer)
  • HY-100532S

    AHPN-13C6

    Isotope-Labeled Compounds RAR/RXR Autophagy Cancer
    CD437- 13C6 is the 13C- and deuterium labeled CD437. CD437 is a selective Retinoic Acid Receptor γ (RARγ) agonist.
    CD437-13C6
  • HY-111573

    RAR/RXR Others
    Anticancer agent 168 is an orally active retinoic acid receptor (RAR/RXR) beta2 agonist with ameliorating effects on spinal cord injury (SCI) .
    KCL-286
  • HY-108532

    RAR/RXR Cancer
    AC-261066 is a potent, orally available and isoform-selective retinoic acid beta2 (RARbeta2) receptor agonist, with a pEC50 of 8.0 .
    AC-261066
  • HY-101108

    AGN 190299

    Tazarotenic acid is the metabolite of Tazarotene. Tazarotenic acid binding to retinoic acid receptors (RARs) is the probable molecular target of retinoid action. Tazarotenic acid has the potential for the research of warty dyskeratoma .
    Tazarotenic acid
  • HY-15388S

    AGN 190168-d8

    Isotope-Labeled Compounds RAR/RXR Autophagy Inflammation/Immunology Cancer
    Tazarotene-d8 is the deuterium labeled Tazarotene. Tazarotene (AGN 190168) is a selective retinoic acid receptor (RAR) agonist for the treatment of plaque psoriasis and acne vulgaris[1][2].
    Tazarotene-d8
  • HY-111839

    CRABP-II ligand 1

    Ligands for Target Protein for PROTAC Cancer
    ATRA-hydroxyimino (CRABP-II ligand 1), the Retinoic acid (ATRA)-based moiety, binds to cIAP1 ligand (Bestatin) via a linker to form SNIPER to degrade CRABP-II in IMR-32 cells .
    ATRA-hydroxyimino
  • HY-105689

    RAR/RXR Others
    AGN 192870 is a RAR neutral antagonist with Kds of 147, 33, and 42 nM for RARα, RARβ, and RARγ, respectively. AGN 192870 shows IC50s of 87 and 32 nM for RARαand RARγ, respectively. AGN 192870 shows RARβ partial agonism . AGN 192870 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    AGN 192870
  • HY-112706

    ROR Inflammation/Immunology
    PF-06747711 is a potent, selective, and orally active retinoic acid receptor-related orphan C2 (RORC2, also known as RORγt) inverse agonist, with an IC50 of 4.1 nM. Anti-skin inflammatory activity .
    PF-06747711
  • HY-101108S

    AGN 190299-d6

    Isotope-Labeled Compounds Drug Metabolite Others
    Tazarotenic acid-d6 is deuterium labeled Tazarotenic acid. Tazarotenic acid is the metabolite of Tazarotene. Tazarotenic acid binding to retinoic acid receptors (RARs) is the probable molecular target of retinoid action. Tazarotenic acid has the potential for the research of warty dyskeratoma .
    Tazarotenic acid-d6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: